Our findings that sHLA-G levels are higher in non-mastectomized breast cancer patients than in mastectomized patients, together with the time-dependent decrease in sHLA-G levels observed in Sayed et al., (2010) study may be translated into possible reliance on sHLA-G as a biomarker for prognosis. The gene discussed is HLA-G; the disease is breast carcinoma.